Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 292 | 48,070 | 33% |
| 2020 | 264 | 32,934 | 36% |
| 2021 | 278 | 43,634 | 39% |
| 2022 | 264 | 45,285 | 41% |
| 2023 | 266 | 45,801 | 43% |
| 2024 | 259 | 44,451 | 45% |
| 2025 from claims | – | 43,282 39,721–45,793 | 46% |
| 2026 forecast | – | 43,944 38,664–50,709 | 46% |
| 2027 forecast | – | 44,522 38,061–53,057 | 47% |
| 2028 forecast | – | 45,105 37,635–55,229 | 47% |
| 2029 forecast | – | 45,692 37,319–57,302 | 47% |
| 2030 forecast | – | 46,284 37,079–59,312 | 48% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 15% of the cases CMS names in New Jersey; 131 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 5% hospital outpatient, 94% surgery center, 1% office. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 588 | 82,565−2.7%/yr | −2.7%/yr | 44.5 | 75% | 85,900 in 2030+0.7%/yr |
| Pennsylvania | 390 | 72,726−1.7%/yr | −1.7%/yr | 52.4 | 80% | 74,300 in 2030+0.4%/yr |
| Massachusetts | 256 | 48,337+1.2%/yr | +1.2%/yr | 50.4 | 83% | 55,500 in 2030+2.3%/yr |
| Connecticut | 117 | 25,053−0.3%/yr | −0.3%/yr | 74.2 | 80% | 30,200 in 2030+3.2%/yr |
| New Hampshire | 45 | 10,8700%/yr | 0%/yr | 47.3 | 79% | 12,900 in 2030+2.8%/yr |
| Rhode Island | 27 | 7,5280%/yr | 0%/yr | 80.9 | 89% | 11,900 in 2030+7.9%/yr |
| Maine | 24 | 5,023−10%/yr | −10%/yr | 31.2 | 86% | 4,850 in 2030−0.6%/yr |
| Vermont | 17 | 4,085−6.1%/yr | −6.1%/yr | 35.4 | 63% | 6,680 in 2030+8.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 23 | 1,908−1.3%/yr | −1.3%/yr | 1.80.9× | 56% | 1,990 in 2030+0.7%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Alcon leads with 23% of company spending on these surgeons in 2025, level with 2024.
In 2025, 20 companies reported engagement with New Jersey’s surgeons worth $491K in consulting, speaking, meals and travel tied to these products, about $1,895 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.